KR20050045980A - Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease - Google Patents

Abstract

The present invention relates to a pharmaceutical composition containing a saponin derivative having an antiallergic effect. The saponin derivatives of the present invention are superior to antiallergic and therapeutic allergy agents, which are known in the art as compounds isolated from ginseng extract. It can be used as a pharmaceutical and health supplement food useful for the prevention and treatment of allergic diseases.

Description

HEALTH SUPPLEMENT FOOD CONTAINING SAPONIN DERIVATIVES ISOLATED FROM GINSENG RADIX FOR PREVENTING AND TREATING ALLERGY-MEDIATED DISEASE}

The present invention relates to a composition containing ginseng saponin derivative having excellent antiallergic efficacy.

Due to the complexity of society and the development of industry and civilization, allergic diseases are increasing every year due to the increase of natural environment pollution, the change of diet, and the weight of stress. In 1980, less than 1% of allergic patients, including atopic dermatitis, increased to more than 5% in the 2000s and more than 10% of potential patients. Allergy is a biochemical phenomenon that shows a specific and modified reaction to foreign substances (antigens, allergens), and when the released substance causes symptoms, allergens are called allergens. This is called. The cause of allergy is a pathological process of the living body that results from an antigenic antibody response, and is generally classified as type 1 to 4 according to the time required to cause the response and the type of complement-mediated. Immediate anaphylaxis, which causes bronchial asthma, allergic rhinitis, hay fever and atopic dermatitis, is a type 1 reaction. This immediate hypersensitivity and allergic reaction is due to various changes that occur in mast cells and the like. Mast cells are degranulation-induced activation of the antigen, binding of the antigen to the Fc receptor, anti-immunoglobulin E (anti-IgE), lectin (Lectin), stimulation of anaphylatoxin, calcium ionopo Caused by drugs such as synthetic cortical stimulating hormones such as Ionopore, compound K48 / 80, codeine, etc. (Tasaka et al., Ann.Allergy 56 , 464, 1986; Chand et al, Eur. J. Pharmacol. , 96 , 227, 1983; Takei et al., J. Pharm. Sci. , 84 , 223, 1995; Ohmori et al., Biol. Pharm. Bull. , 18 , 683, 1995)

Recently, various studies have been conducted due to the increase of allergic diseases, and progress has been made in the identification and treatment of allergic diseases due to the development of radical immunology, but the development of drugs that can cure allergic diseases sufficiently. Existing allergic disease treatments include side effects such as dizziness, neurosensitivity, drowsiness and fatigue, so it is necessary to develop an allergic disease treatment agent that has excellent side effects while having fewer side effects.

Panax ginseng CA Meyer is a perennial root that belongs to the genus Ogapiaceae ginseng according to the plant taxonomy. About 1 species of ginseng (1) Korean ginseng ( Panax ginseng CA Meyer) is located in the Far East of Asia (33 to 48 ° north: Korea, North Manchuria, It is native to parts of Russia and has very good efficacy. (2) American Ginseng ( Panax quinquefolium L.) grows and grows in the United States and Canada, and (3) Panax notoginseng FH Chen is located in the southwestern part of Guangxi province in southeastern Yunnan Province, China. Wild or cultivated in the region, and (4) Panax japonicus CA Meyer is known to be distributed in Japan, southwest China and Nepal.

        Ginseng is not only stored as a commodity in new agricultural plants, but has been used as a valuable medicine since ancient times. Many pharmacological experiments to date have revealed that ginseng strengthens the nonspecific resistance of the body to stress and has an acidic action. In addition, hypertension, insulin action enhancement, hypoglycemic effect in alloxan diabetic mice, liver RNA synthesis, protein synthesis, sugar and lipid metabolism promoting effect, and anticancer effect was found.

The ginseng has been used for various diseases such as psychiatric diseases, nervous system diseases and diabetes in the form of herbal medicine mainly in Asian countries such as Korea, China and Japan, and saponins, the main components of the ginseng, are tonic, gangjeong, soothing It is known to have effects on hematopoiesis and antihypertension. (和 漢 藥 百科 圖鑑, Vol. 1, pp. 1-8, Nambatsune-Hiki, Hoi-Kusa, 1980)

Ginseng is used in the form of red ginseng, which is produced by heat-treating white ginseng or ginseng dried at room temperature, or ginseng prepared by heating at 120 to 180 ° C.

The root of ginseng contains about 5.22% of ginseng saponin, which is a mixture of 13 or more saponins, among which the content of ginsenosides Rb1, Rc, and Rg1 is relatively high. Doha Hyangje Dictionary, Yeonglimsa, p439-443 1998)

There are about 300 kinds of enterobacteria of healthy people from the mouth to the rectum, and more than 98% of them are anaerobic bacteria, for example, Bacterioides, Eubacterium, Peptokocacea ( Peptococcaceae) and Bifidobacterium. These intestinal bacteria biologically convert the compounds contained in food or drugs, and the resulting transformants are often more physiologically active than the original compounds. One such example is saponins such as ginsenosides Rb1, Rb2, and Rc, which are main components in ginseng. Dual ginsenosides Rb1, Rb2 and Rc are metabolized mainly to compound K via ginsenoside Rd by the human intestinal flora. Known strains catalyzing this metabolic process are the Provotella oris and Fusobacterium K-60 strains. Meanwhile, when ginseng saponin is treated with a weak acid, it is converted to ginsenoside Rg3, and the compound is converted to ginsenoside Rh2 by intestinal bacteria such as Fusobacterium K-60 strain. Compound K (20-Ο-β-D-glucopyranosyl-20 (S) -protopanaxadiol) and ginsenoside Rh2 produced in this case are known to inhibit cytotoxicity against cancer cells or cancer metastasis of cancer cells. (Mochizuki , M. et al., Biol. Pharm. Bull ., 18: 1197-1202, 1995; Wakabayashi, C., H. et al., Oncol. Res. , 9: 411-417, 1998)

However, the prior art discloses no use of the composition containing the saponin derivative of the present invention as an agent for preventing and treating allergic diseases.

The present inventors have found that various kinds of saponin derivative compounds isolated from the ginseng saponin fraction produced by treating ginseng with lactic acid bacteria and enterobacteriaceae have an excellent therapeutic effect on allergic diseases and completed the present invention.

It is an object of the present invention to provide a composition containing a saponin derivative isolated from a ginseng saponin fraction effective for treating allergic related diseases.

In accordance with the above object, the present invention provides a composition for the prevention and treatment of allergic related diseases comprising saponin derivatives selected from the group consisting of ginsenosides Rc, Rd, F2 and compound K isolated from ginseng extract.

The composition for the prevention and treatment of allergic diseases of the present invention, the ginseng saponin derivative comprises 0.02 to 90% by weight relative to the total weight of the composition.

The saponin derivative of the present invention can be separated by performing a conventional method for separating saponin derivatives,

Looking specifically at the separation process,

(1) Acquisition process of saponin fraction

First, about 1 to 10 times 15 times, preferably about 5 to 10 times water, lower alcohol or about 1: 0.1 to 1:10, preferably 1: 1 to 1: 3 to the dried ginseng raw material. A mixed solvent having a mixing ratio of 20 to 100 ° C., preferably 70 to 100 ° C. at an extraction temperature of about 1 hour to 2 days, preferably about 2 hours to 1 day, extraction such as ultrasonic extraction, reflux extraction, and cooling After carrying out the process, it is dissolved in water and suspended, followed by adding about 1 to 5 times the volume of butanol, propanol, acetone solvent, and preferably butanol solvent to obtain a saponin fraction containing a large amount of saponin.

(2) Saponin fraction special treatment process

Biological strains by adding lactic acid bacteria or intestinal bacteria to the saponin fraction obtained in the above step and culturing at a culture temperature of 20 to 50 ℃, preferably 25 to 40 ℃ for 12 hours to 4 days, preferably 24 hours to 3 days Obtained ginseng saponin fraction.

Through this process, the compounds ginsenoside-Rb1, ginsenoside-Rb2, ginsenoside-Rc and the like contained in the raw material are bioconverted through lactic acid bacteria or intestinal bacteria and converted into the final metabolite compound K.

The ginseng raw materials include ginseng and processed ginseng products and by-products, and preferably include ginseng, red ginseng, white ginseng, rice ginseng, ginseng leaves, ginseng extract and powdered ginseng.

The lactic acid bacteria that can be used in the ginseng culture may be any one that can metabolize ginseng saponin to produce a compound K, which is a bioconverter, preferably Bifidobacterium lactic acid bacteria, more preferably Bifidobacterium Terium K-103 (Kim, Kyung Hee University, Dong-Hyun Kim, Arch. Pharm. Res. , 21 , 54-61, 1988), Bifidobacterium K-506 (Kyung Hee University, Kim, Dong-Hyun University, Arch. Pharm. Res. , 21 , 54-61, 1988), Bifidobacterium K-513 (Professor Dong-Hyun Kim, Kyung Hee University, Arch. Pharm.Res . , 21 , 54-61, 1988), Bifidobacterium K-525 (Professor Kim Dong-Hyun, Kyung Hee University) , Arch. Pharm.Res . , 21 , 54-61, 1988), Bifidobacterium KK-1 (Accession No .: KCCM 10364), Bifidobacterium KK-2 (Accession No .: KCCM 10365), among lactic acid bacteria One or a mixture of these strains can be used.

Intestinal bacteria that can be used in the culture also can be any one that can also metabolize ginseng saponin to produce a compound K, a bioconverter, preferably Bacterioides genus, Fusobacterium genus, Intestinal bacteria of the genus Eubacterium, more preferably bacteroid JY-6 (Kim Hee University Pharmacy, Dong-Hyun Kim, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000), Bacterides HJ-15 strain (Kyung Hee University) Dong-Hyun Kim, Ph.D., Biol.Pharm.Bull . , 23 , pp1481-1485, 2000), Fusobacterium K-60 (Kyung-Hee University, Ph.D., Dong-Hyun Kim, Biol. Pharm.Bul . , 23 , pp1481-1485, 2000) Therium L-8 (Kim Hee University, Professor Dong-Hyun Kim, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000) is available.

(3) Saponin derivative separation process

The saponin fraction obtained in step (1) or (2) is subjected to silica gel column chromatography to separate various kinds of saponin derivatives in separated form.

In another aspect, the present invention provides all related ginseng products that can be processed in the market containing the ginseng extract specially processed by the above-described manufacturing process.

Such processable related ginseng products include ginseng dry powder, extract, ampoule, tea, tablets and the like.

Raw or specially treated ginseng saponin fraction and ginseng saponin derivatives isolated therefrom are equivalent to or better than conventional antiallergic drugs in anti-allergic effect experiments in rat mast cells using RBL-2H3 cells. Excellent allergic inhibitory effect.

Accordingly, the present invention provides a pharmaceutical composition for the prevention and treatment of allergic diseases including various kinds of saponin derivatives isolated from the saponin fraction.

Specifically, the allergy-related diseases include diseases such as rhinitis, dermatitis, asthma and autoimmune deficiency.

Compositions comprising saponin derivatives isolated from the ginseng saponin fraction of the present invention may further comprise suitable carriers, excipients and diluents according to conventional methods.

Carriers, excipients, and diluents that may be included in a composition comprising saponin derivatives isolated from the ginseng saponin fraction of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia Rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil Can be.

Compositions comprising saponin derivatives isolated from the ginseng saponin fraction according to the present invention may be prepared in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. It can be formulated and used in the form of sterile injectable solutions.

The amount of saponin derivatives isolated from the ginseng saponin fraction of the present invention may vary depending on the age, sex and weight of the patient, but may be administered once to several times daily in an amount of 0.1 to 100 mg / kg. In addition, the dose of the saponin derivative isolated from the ginseng saponin fraction may be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The composition comprising a saponin derivative isolated from the ginseng saponin fraction of the present invention can be used in various forms, such as drugs, food and beverages for the prevention and treatment of allergic diseases. Examples of foods to which the derivatives can be added include various foods, beverages, gums, teas, vitamin complexes, and health supplements.

The saponin derivative itself isolated from the ginseng saponin fraction of the present invention has almost no toxicity and side effects, and thus is a drug that can be used safely even when taken for a long time.

Saponin derivatives isolated from the ginseng saponin fraction of the present invention may be added to food or beverage for the purpose of preventing allergic diseases. At this time, the amount of the saponin derivatives separated from the ginseng saponin fraction in the food or beverage is generally added to 0.01 to 15% by weight of the total food weight of the health food composition of the present invention, the food health beverage composition is based on 100 m1 In the range of 0.02 to 0.1 g, preferably 0.3 to 1 g.

The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the fractions or compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of said natural carbohydrate is generally about 1-20 g, preferably about 5-12 g per 100 m1 of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention is described in more detail based on the following examples, although the present invention is not limited thereto.

Example 1 Isolation of Ginseng Saponin Fraction and Saponin Derivatives

10 kg capacity of methanol was added to 1 kg of dried 6-year-old white ginseng purchased from Gyeongdong Market, and cooled 5 times at room temperature, concentrated under reduced pressure to obtain 50 g of methanol extract (yield: 5%), and 300 ml of distilled water was added thereto. After addition and suspension, 500 ml of butanol was added to the suspension, and the mixture was fractionated three times to obtain 15 g of a saponin fraction, which was used as sample (1) .

This was added to water 1500㎖ saponin fractions 15g of Enterobacteriaceae bakteriohyi des JY-6 (Adv Kyung Dong - Hyun camels, Biol. Pharm. Bull., 23, pp1481-1485, 2000) a strain 15g (Kyung Dong - Hyun Adv camels, Biol. Pharm. Bull. , 23 , pp1481-1485, 2000) was added, and cultured at 37 ° C. for 72 hours. The culture was extracted twice with 1000 mL of butanol, concentrated under reduced pressure, and dried to obtain 6 g of the treated saponin fraction powder. Using as a sample (2) , 5 g of this saponin fraction was subjected to silica gel column chromatography (column size: 3.5 × 60 cm developing solvent: CHCl ₃ -MeOH = 10: 1) to obtain ginsenoside Rc 20 mg and ginsenoside Rd. 20 mg, ginsenoside F2 70 mg, ginsenoside Mc 10 mg, compound K 450 mg, 20 mg of 20 (S) -protopanaxadiol and 2 mg of 20 (R) -protopanaxadiol were obtained, respectively.

Example 2. Preparation of Ginseng Fermentation

To 1 kg of dried 6-year-old white ginseng purchased from Gyeongdong market, 50% water of 10 times was added, extracted three times at 50 ^o C, concentrated to obtain 70 g of extract (yield: 7%), and 300 ml of After distilled water was suspended, 500 g of Bifidobacterium KK-1 (KCCM 10364) and Bifidobacterium KK-2 (KCCM 10365) strains were added to 500 ml of this suspension at 37 ° C. Incubated for 72 hours, concentrated under reduced pressure and dried to obtain 120 g of a processed saponin fraction powder sample ( 3 ).

Experimental Example 1: Allergic inhibitory effect of saponin derivatives

(1) Experiment with RBL-2H3 cell line.

To compare the antiallergic effect of the saponin fraction obtained in Example 1 of the present invention and the saponin derivatives isolated therefrom, Inagaki et al .; Int. Arch. Allergy Appl. Immunol., 87 , pp254-259, 1988) according to the anti-allergic effect test method described in the following experiment was carried out.

DBL (Dulbeccos' modified Eagle's medium, Sigma, 22256) containing 10% FBS (fetal bovine serum) and L-glutamine in rat mast cell line (RB-2H3 cell line, Cat Cell No. 22256) (Sigma D-5648) was incubated for 2 hours in a humidified 5% CO ₂ incubator at 37 ° C., and the adherent cells were suspended using trypsin-EDTA solution. It was used for this experiment.

The RBL-2H3 cells were aliquoted into ⁵ wells of ⁵ × 10 ⁵ cells / well, followed by sensitization by incubating for 12 hours with 0.5 μg / ml of mouse monoclonal IgE. The cells were washed with 0.5 ml of siraganian buffer (119 mM NaCl, 5 mM KCl, 0.4 mM MgCl ₂ , 25 mM PIPES, 40 mM NaOH, pH 7.2) and then again 0.16 ml of siraguanian buffer (5.6 mM glucose). , 1mM CaCl ₂ , 0.1% BSA was added) and then incubated at 37 ° C. for 10 minutes. And the saponin fraction, the saponin derivatives and the control drug DSCG isolated in Example 1 each added 0.04 ml, and after 20 minutes with 0.02 ml of the antigen (DNP-BSA 1㎍ / ml) for 10 minutes at 37 ℃ Cells were activated and centrifuged at 2000 rpm for 10 minutes to transfer 0.025 ml of supernatant to 96 wells. To this was added 0.025 ml of substrate solution 1 mM p-NAG (a solution of p-nitrophenyl-N-acetyl-β-D-glucoamide) in 0.1M citrate buffer to pH 4.5, which was then heated at 37 ° C. After incubation for 10 minutes, 0.2 ml of 0.1 M Na ₂ CO ₃ / NaHCO ₃ was added to stop the reaction, and the respective absorbances were measured with an ELISA analyzer at 405 nm.

As shown in Table 1, the saponin derivatives isolated in Example 1 were found to be equal to or superior to the allergic effect of the control drug DSCG (Disodium Cromoglycate, Sigma, C-0399) using the RBL-2H3 cell line. In addition, intestinal bacteria treated ginseng saponin fraction, ginsenosides Rc, Rd, F2, Mc and Compound K was confirmed that the inhibitory effect is significantly superior to DSCG.

Antiallergic Effect in RBL Cells Treatment Sample IC ₅₀ (μg / ml) Saponin Fraction Samples (1) > 0.2 Saponin Fraction Samples (2) 0.1 Ginseng Fermentation Samples (3) 0.15 Ginsenoside Rc > 0.2 Ginsenoside Rd > 0.2 Ginsenoside F2 0.08 Ginsenoside Mc 0.03 Compound K 0.02 DSCG (positive control) 0.498

(2) Passive Percutaneous Anaphylaxis Experiment Using Animal Model

In addition, to determine the effect of saponin fractions of Example 1, saponin derivatives and positive control DSCG (Disodium Cromoglycate, Sigma, C-0399) on allergy using passive cutaneous anaphylaxis experimental animal models The same experiment was performed.

First, the back of the mouse (ICR-based Korean animal) in which 10 g of a solution of IgE serum of DNP-HSA (Dinitrophenol-human serum albumin (Sigma, A-6661) diluted with physiological saline was anesthetized with ether. (50 µl), and manually sensitized. After 48 hours, 0.2 ml of saline solution containing 0.2 mg of DNP-HSA and 1.6 mg of evans blue was injected into the tail vein and killed by cervical dislocation 30 minutes later. The amount of Evans blue pigment leaked by the back and the like was measured. A portion of the back of the mouse (1cm ² of the site where IgE was injected) was cut out into a test tube, and 0.7 ml of 1N-KOH was added thereto and incubated overnight at 37 ° C. 4 ml of 0.6N phosphate-acetone mixed solution (5:13) was added to the test tube, followed by shaking with Vortex and filtration to give colorimetric determination at 620 nm.

Samples were dissolved or suspended in physiological saline and administered orally one hour before administration of antigen (DNP-BSA).

As shown in Table 2 below, allergens using the passive cutaneous anaphylaxis experimental animal model of DSCG (Disodium Cromoglycate, Sigma, C-0399), the saponin fractions and saponin derivatives isolated in Example 1, were used as control. In addition, the inhibitory effect on E. coli could be confirmed to be equal to or superior, and in particular, ginsenosides Rd, F2 and Compound K showed strong inhibitory effects upon intraperitoneal administration. ((-) Not shown)

Results of Passive Transdermal Anaphylaxis Effect Treatment Sample Capacity (mg / kg) % Inhibition Oral administration Intraperitoneal administration Saponin Fraction (Sample 1) 50 34 - Saponin Fraction (Sample 2) 50 47 - Ginsenoside Rc 25 - 10 Ginsenoside Rd 25 - 45 Ginsenoside F2 25 - 57 Compound K 25 98 99 DSCG (positive control) 37

In conclusion, the chemical treatment and biological treatment of ginseng produced a large amount of saponin derivatives effective for the prevention and treatment of allergic diseases. These saponin derivatives were allergic or related. It has been found that it can be effective in the prevention and treatment of diseases.

Hereinafter, an example of the preparation of the pharmaceutical composition will be described, but it is not intended to limit the present invention but merely to explain in detail.

Formulation Example 1 Preparation of Powder

According to the preparation method of powder in the pharmacopeia formulation, it is prepared in the following component content per packet.

Compound K 50 mg

Lactose · ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Talc 10 mg

Formulation Example 2 Preparation of Tablet

According to the preparation method of tablets in the pharmacopeia formulation, it is prepared in the following component content per tablet.

Compound K ㆍ ················ 50 mg

Corn starch ㆍ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Lactose · ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Magnesium Stearate 2 mg

Formulation Example 3 Preparation of Capsule

According to the preparation method of the capsule in the general formulation of the pharmacopeia, it is prepared in the following component content per capsule.

Compound K 50 mg

Corn starch ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 100 mg

Lactose ····················· 100 mg

Magnesium stearate 2 mg

Formulation Example 4 Preparation of Injection

According to the preparation method of injection in the pharmacopeia formulation, it is prepared in the following component content per ampoules (2 ml).

Compound K 50 mg

Sterile distilled water for injection ㆍ ·············

pH regulator ㆍ ··················

Formulation Example 5 Preparation of Liquid

According to the preparation method of the liquid formulation in the Pharmacopoeia General Formulation, it is prepared in the following component content per 100 ml of the liquid formulation.

Compound K 50 mg

Heterosaccharides ················· 10 g

Mannitol ···················· 5 g

Purified water ㆍ ···················

In addition, the health beverage is prepared as follows.

Compound K 0.1 to 80%, sugar 5 to 10%, citric acid 0.05 to 0.3%, caramel 0.005 to 0.02%, vitamin C 0.1 to 1% of the additives were mixed and 79 to 94% purified water was mixed to make a syrup, The syrup was sterilized at 85 to 98 ° C. for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, and then a carbonated beverage containing ginseng saponin was prepared by injecting carbon dioxide gas at 0.5 to 0.82%.

Instant disinfection by homogeneously mixing compound K with subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). Health drinks were prepared by packaging in small packaging containers such as plastic bottles.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and use purpose.

Compositions containing saponin derivatives isolated from processed ginseng, which have undergone chemical treatments such as raw ginseng or acid treatment and biological treatment such as lactic acid bacteria culture, have an activity of effectively inhibiting allergic diseases and thus preventing allergic diseases. And since it shows a therapeutic effect, it can be usefully used as a prophylactic and therapeutic agent for allergic diseases.

Claims (2)

A dietary supplement for the prevention and treatment of allergic diseases, comprising compound K (20-Ο-β-D-glucopyranosyl-20 (S) -protopanaxadiol) as an active ingredient. The dietary supplement of claim 1, wherein the allergic disease is selected from asthma, rhinitis, and dermatitis.